Brenda Y Hernandez
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Cyanobacteria, cyanotoxins, and liver cancer development
Open Date: 2024-05-01
Close Date: 2029-04-30
Grant: Close
Hawaiʻi Translational Cancer Research Program
Open Date: 2023-09-19
Close Date: 2026-07-31
Grant: Close
NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER
Open Date: 2022-12-23
Close Date: 2023-12-22
Grant: Close
NCI PATTERNS OF CARE (POC)/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2019 (URINARY BLADDER CANCER AND KIDNEY CANCER)
Open Date: 2021-04-05
Close Date: 2022-04-04
Grant: Close
SEER-LINKED PEDIATRIC CANCER WHOLE SLIDE IMAGING PILOT - UNIVERSITY OF HAWAII HHSN261201800011I POP 8/20/2020-8/19/2021
Open Date: 2020-08-20
Close Date: 2021-08-19
Articles (32)
Year:
2026
In the 2021 Report on Carcinogens, the National Toxicology Program of the United States listed 63 known human carcinogens. While many of the listed agents are environmental factors, only 2, aflatoxin and vinyl chloride, have been definitely linked to types of liver cancer. Aflatoxin is well known to increase the risk of HCC, while vinyl chloride is a cause of angiosarcoma of the liver. A number of other environmental factors have been studied for an association with liver cancers, such as air pollution, perfluoroalkyl and polyfluoroalkyl substances, cyanobacteria, pesticides, aristolochic acid, polycyclic aromatic hydrocarbons, asbestos, arsenic, and organic solvents; however, limited evidence exists for these exposures. It is the goal of this review article to examine what is currently known about environmental risk factors and liver cancer and suggest which ones should have the highest priority for further research.
Year:
2025
Background: Worldwide trends support the increasing contribution of hepatic steatosis to the incidence of hepatocellular carcinoma (HCC). This study investigates if similar changes are seen in Hawaii, where the incidence of HCC is higher than in most of the United States. Methods: This is a retrospective study of 1,651 patients diagnosed with HCC (1991–2023) that includes 60% to 70% of HCC cases in Hawaii. We evaluated changes in patient demographics, risk factors, and disease etiology over the past three decades. Results: From 1991 to 2023, there were significant increases in the proportion of HCC cases attributable to metabolic dysfunction–associated steatotic liver disease (MASLD), coinciding with an increase in the prevalence of metabolic risk factors including obesity, diabetes, hyperlipidemia, and hypertension. Cases with a history of smoking also increased through 2020. Conversely, HCC cases presenting with cirrhosis alone decreased. Hepatitis C virus (HCV)-associated cases increased through 2015 and then tapered, whereas Hepatitis B virus (HBV)-associated cases decreased through 2020. There was no significant change in the proportion of alcohol-associated cases. Conclusions: Although HBV continues to be a major contributor to HCC in Hawaii, HCV-related HCC cases have tapered, whereas metabolic risk factors for HCC and cases attributable to MASLD have increased over time, paralleling overall trends observed in the United States. Efforts are needed to manage these metabolic factors to address the burden of HCC. Impact: Although Hawaii continues to have a large burden of viral hepatitis–related HCC, metabolic factors and MASLD have affected the pathogenesis of liver cancer in Hawaii over the past three decades.
Year:
2025
Supplementary Table 1. The average of the sum of pathology reports during March to May of 2018 and 2019 (pre-pandemic period) compared to the sum of pathology reports during March to May 2020 (pandemic period) by cancer site.
Year:
2025
Figure S1. Pathology report volume in 2020 compared to the volume of COVID-19 cases by geographic region and month. 1Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2023, March 27.
Year:
2025
Background: Filipino Americans constitute 12% and 4% of the respective populations of Hawaii and California, with a large proportion of immigrants experiencing increasing cancer rates. This study investigated the incidence of colorectal, breast, and prostate cancers by generational status in the Multiethnic Cohort. Methods: We analyzed 10,495 Filipino Multiethnic Cohort first-, second-, and third-generation participants, in which 26.8% were of mixed race and ethnicity. Linkage to statewide cancer registries identified 375 breast, 249 colorectal, and 436 prostate cancer incident cases. Cox models were used to calculate HRs and 95% confidence intervals (CI) for the association between generational status and cancer incidence. Models were adjusted for age at cohort entry and cancer-specific covariates that were chosen based on stepwise regression. Results: Compared with the first generation, colorectal cancer showed a significantly higher incidence in the second and third generations with respective HRs of 1.43 (95% CI, 1.04, 1.98) and 1.76 (95% CI, 1.29, 2.38). This association was attenuated after adjustment for relevant covariates. Breast cancer incidence was elevated in the third versus first generation (HR = 1.29; 95% CI, 1.01, 1.63) even in the fully adjusted model, whereas little difference was observed for prostate cancer. Conclusions: In this prospective study, we found differences in incidence by generational status, specifically colorectal cancer among men and female breast cancer. Impact: Understanding behavioral changes due to acculturation is warranted to mitigate cancer risks in migrant populations.
Year:
2024
Year:
2024
Year:
2024
Current characteristics of early onset colorectal cancer (EOCRC) in the United States have been mainly studied in Whites, African Americans, and Hispanics, but little is known in regard to EOCRC in Asians and Native Hawaiians in the US. EOCRC was examined in Hawaii’s multiethnic population. Data from the Hawaii Tumor Registry was used to analyze colorectal cancer (CRC) cases diagnosed in Hawaii from 2000–2019 by subsite, age, gender, ethnicity, and stage. Ethnicity analyses were limited to 3524 CRC cases, diagnosed between 2015–2019. Average annual 5-year age-adjusted incidence and mortality rates, average annual percent change over time, and 5-year survival were evaluated. Group comparisons utilized Chi-square and binomial proportion tests. Overall CRC incidence and mortality declined and were more pronounced for colon than rectal/rectosigmoid junction cancers. Colon cancer incidence rates significantly increased 1.46-fold for cases diagnosed under 45 years of age and rectal/rectosigmoid cancers significantly increased 1.54-fold for cases 45–54 years of age. CRC incidence increased sharply for females aged 45–54 years from 2000–2009 to 2010–2019, and increases in colon and rectal/rectosigmoid cancer among individuals aged 45–54 were higher for females. Among both sexes, the increase in rectal/rectosigmoid cancer incidence for individuals under 55 years was highest for stage I cancers. Overall, the mean (SD) age of CRC diagnosis was 5–10 years earlier for Native Hawaiians (60.6 [13.3] years) compared with Japanese, Chinese, Filipinos, Whites, and Other Asians (p < 0.001). Native Hawaiians constituted a greater proportion of CRC diagnosed under age 55 years and, conversely, a smaller proportion of cases 55 years and older compared with Japanese, Chinese, Filipinos, Whites, and Other Asians. Native Hawaiians had a significantly higher CRC-related mortality rate (14.5 per 100,000 [95% CI: 12.4, 16.8]) compared with Japanese (10.7 per 100,000 [95% CI: 9.3, 12.3]) and a significantly lower CRC survival rate (62.2% [95% CI: 59.1, 65.2]) compared with Japanese (71.9% [95% CI: 69.9, 73.8]), Filipinos (71.9% [95% CI: 69.2, 74.4]), Chinese (70.2% [95% CI: 65.5, 74.4]), Whites (69.3% [95% CI: 67.1, 71.4]), and Other Asians (71.7% [95% CI: 66.2, 76.5]). In our diverse US population, Native Hawaiians contribute disproportionately to EOCRC and present 5–10 years earlier than Whites, Japanese, Chinese, and Filipinos. EOCRCs are increasing faster in females than males in Hawaii, which differs from trends in the general US population. Emerging ethnic disparities in EOCRC in the US speak to the need for studies on targeted interventions and ethnic-specific risk factors for EOCRC.
Year:
2024
Background: Filipino Americans constitute 12% and 4% of the respective populations of Hawaii and California, with a large proportion of immigrants experiencing increasing cancer rates. This study investigated the incidence of colorectal, breast, and prostate cancers by generational status in the Multiethnic Cohort. Methods: We analyzed 10,495 Filipino Multiethnic Cohort first-, second-, and third-generation participants, in which 26.8% were of mixed race and ethnicity. Linkage to statewide cancer registries identified 375 breast, 249 colorectal, and 436 prostate cancer incident cases. Cox models were used to calculate HRs and 95% confidence intervals (CI) for the association between generational status and cancer incidence. Models were adjusted for age at cohort entry and cancer-specific covariates that were chosen based on stepwise regression. Results: Compared with the first generation, colorectal cancer showed a significantly higher incidence in the second and third generations with respective HRs of 1.43 (95% CI, 1.04, 1.98) and 1.76 (95% CI, 1.29, 2.38). This association was attenuated after adjustment for relevant covariates. Breast cancer incidence was elevated in the third versus first generation (HR = 1.29; 95% CI, 1.01, 1.63) even in the fully adjusted model, whereas little difference was observed for prostate cancer. Conclusions: In this prospective study, we found differences in incidence by generational status, specifically colorectal cancer among men and female breast cancer. Impact: Understanding behavioral changes due to acculturation is warranted to mitigate cancer risks in migrant populations.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (50)
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
John Groopman
Edith Schoenrich Professor of Preventive Medicine
Johns Hopkins University
Beth Karlan
Vice Chair
University of California, Los Angeles
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Martin Widschwendter
Professor; Director
University of Innsbruck
Martin Köbel
Associate Professor
University of Calgary
Scarlett L. Gomez
University of California, San Francisco
Song-Yi Park
-
James D Brenton
University of Cambridge
Cezary Cybulski
Pomeranian Medical University
Grazyna Badowski
U54 NCI grant Biostatistics Shared Resource Core leader
University of Guam
Linda Cook
Professor
University of Colorado Cancer Center
Xun Shi
Professor
Dartmouth College
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Joellen Schilkdraut
Professor
Emory University
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Usha Menon
Professor of Gynaecological Oncology
University College London
Huann-Sheng Chen
National Institutes of Health
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
C Blake Gilks
-
Peter Fasching
-
Francesmary Modugno
University of Pittsburgh
Alexander Hein
-
Dale Garsed
University of Melbourne
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Gertraud Maskarinec
Professor and Associate Director for Research Education
University of Hawaii
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Loic Le Marchand
Professor
University of Hawaii
Jennifer Anne Doherty
Professor
University of Utah
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Daniel E Spratt
Chair
University Hospitals Seidman Cancer Center
Jan Lubiński
Head of Dept
Pomeranian Medical University
Veronica Setiawan
Associate Professor
University of Southern California
Mona El-Bahrawy
Imperial College London
Aleksandra Gentry-Maharaj
University College London
David G. Huntsman
The University of British Columbia
Mindy DeRouen
Assistant Professor
New Mexico State University
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Aline Talhouk
Assistant Professor
The University of British Columbia
Stephen Schwartz
Professor
Fred Hutchinson Cancer Research Center
Make your next move.
Prepare your application
Review drafts before you send them.